Dysfunctional Central Venous Access Devices (CVADS)
Conditions
Keywords
CVADS
Brief summary
This was a Phase IV, open-label, single-arm, multicenter trial that was to be conducted at \ 60 sites in the United States. Approximately 300 pediatric subjects with dysfunctional CVADs (including catheters with valves, multiple lumens, umbilical catheters, and implanted ports) were to be treated with up to two serially instilled doses of Cathflo Activase.
Interventions
DRUGCathflo Activase (Alteplase)
Sponsors
Genentech, Inc.
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
No
Inclusion criteria
Subjects had to meet the following inclusion criteria to be eligible for study entry: * Less than 17 years of age * Clinically stable * Occlusion of CVAD (including catheters with valves, multiple lumens, umbilical catheters, and implanted ports) * For subjects who weighed \>= 10 kg, inability to withdraw 3 mL of blood from the CVAD * For subjects who weighed \< 10 kg, inability to withdraw 1 mL of blood from the CVAD * Ability to infuse fluids at the volume necessary to instill Cathflo Activase into the CVAD * Written informed consent and assent (if appropriate) provided by parent or legal guardian and compliance with study assessments for the full duration of the study
Exclusion criteria
* Ability to withdraw blood following subject repositioning * CVAD insertion \< 48 hours prior to enrollment * Selected study catheter implanted specifically for hemodialysis * Evidence of mechanical, non-thrombotic occlusion of the CVAD (e.g., kink in the CVAD or suture constricting the catheter) * Previous enrollment in this study * Use of fibrinolytic agent (e.g., alteplase, reteplase, tenecteplase, urokinase, streptokinase) within 24 hours of enrollment * At high risk for bleeding events, embolic complications (i.e., recent pulmonary embolism, deep vein thrombosis, endarterectomy, clinically significant right-to-left shunt) in the opinion of the investigator, or with known condition for which bleeding constituted a significant hazard * Known hypersensitivity to alteplase or any component of the formulation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the safety, as measured by the incidence of intracranial hemorrhage during the treatment with Cathflo Activase, in restoring function to dysfunctional CVADs in pediatric populations. | — |
Secondary
| Measure | Time frame |
|---|---|
| To estimate the rate of restoration of function to dysfunctional CVADs following administration of up to two instillations of Cathflo Activase. | — |
Outcome results
None listed